Skip to main content
Skip to footer
Home
About us
Our Business
Strategy and business model
Management
Board of Directors
Contact us
Pipeline
Our Science
Pipeline overview
Projects
Rugocrixan
Fosrugocrixan
Business Development
IP
Publications
Therapeutic areas
Myocardial infarction
Ovarian cancer
Investors
Presentations
Press Releases
Financial Reports
Financial Calendar
Events
The Share
Sustainability
Corporate Governance
Articles of Association
Annual General Meeting
Board Committee
Board
CEO and Management
Auditors
Certified Adviser
Home
About us
Our Business
Strategy and business model
Management
Board of Directors
Contact us
Pipeline
Our Science
Pipeline overview
Projects
Rugocrixan
Fosrugocrixan
Business Development
IP
Publications
Therapeutic areas
Myocardial infarction
Ovarian cancer
Investors
Presentations
Press Releases
Financial Reports
Financial Calendar
Events
The Share
Sustainability
Corporate Governance
Articles of Association
Annual General Meeting
Board Committee
Board
CEO and Management
Auditors
Certified Adviser
Start
>
News
News
Kancera AB files patent for HDAC6 inhibitors against cancer
Update on the result of the collaboration between Kancera and Thomas Helleday
Full Year Report for Kancera AB (publ) 2013 January 1 – December 31, 2013
Kancera initiates the development of a vaccine against ROR to prevent relapse of cancer
Kancera announces the discovery of a new class of compounds against cancer
Interim Report for Kancera AB (publ) Q3 2013
Interim Report for Kancera AB (publ) Q2 2013
Kancera is awarded € 950,000 for the development of drugs to treat severe parasitic diseases
Kancera; Update regarding the ROR project
Interim Report for Kancera AB (publ) Q1 2013
